Upcoming event
40th Annual EAU Congress
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROonco24, UROwebinar, Webinar
Show all

IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

September 2022

View

Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

September 2022

View

Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)

September 2022

View

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

The Lancet Oncology, May 2022

View

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

View

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564

View

LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data

View

Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study

View

Protective effect of LCZ696 on kidney function after partial nephrectomy

View

Adjuvant therapy after surgical resection of nonmetastatic renal-cell carcinoma: One size does not fit all

View

Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab

View

Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis

View
PreviousNext